| Advanced drug delivery systems of curcumin for cancer chemoprevention. | |
| | |
MedLine Citation:
|
PMID: 21546540 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Since ancient times, chemopreventive agents have been used to treat/prevent several diseases including cancer. They are found to elicit a spectrum of potent responses including anti-inflammatory, antioxidant, antiproliferative, anticarcinogenic, and antiangiogenic activity in various cell cultures and some animal studies. Research over the past 4 decades has shown that chemopreventives affect a number of proteins involved in various molecular pathways that regulate inflammatory and carcinogenic responses in a cell. Various enzymes, transcription factors, receptors, and adhesion proteins are also affected by chemopreventives. Although, these natural compounds have shown significant efficacy in cell culture studies, they elicited limited efficacy in various clinical studies. Their introduction into the clinical setting is hindered largely by their poor solubility, rapid metabolism, or a combination of both, ultimately resulting in poor bioavailability upon oral administration. Therefore, to circumvent these limitations and to ease their transition to clinics, alternate strategies should be explored. Drug delivery systems such as nanoparticles, liposomes, microemulsions, and polymeric implantable devices are emerging as one of the viable alternatives that have been shown to deliver therapeutic concentrations of various potent chemopreventives such as curcumin, ellagic acid, green tea polyphenols, and resveratrol into the systemic circulation. In this review article, we have attempted to provide a comprehensive outlook for these delivery approaches, using curcumin as a model agent, and discussed future strategies to enable the introduction of these highly potent chemopreventives into a physician's armamentarium. |
| | |
Authors:
|
Shyam S Bansal; Mehak Goel; Farrukh Aqil; Manicka V Vadhanam; Ramesh C Gupta |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review Date: 2011-05-05 |
Journal Detail:
|
Title: Cancer prevention research (Philadelphia, Pa.) Volume: 4 ISSN: 1940-6215 ISO Abbreviation: Cancer Prev Res (Phila) Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-08-05 Completed Date: 2012-01-05 Revised Date: 2013-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 101479409 Medline TA: Cancer Prev Res (Phila) Country: United States |
Other Details:
|
Languages: eng Pagination: 1158-71 Citation Subset: IM |
Affiliation:
|
Department of Pharmacology and Toxicology, University of Louisville Health Science Center, Louisville, Kentucky, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anticarcinogenic Agents / pharmacology* Chemoprevention / methods* Curcumin / administration & dosage* Drug Delivery Systems* Emulsions Humans Lactic Acid / chemistry Liposomes / metabolism Mice Microscopy, Atomic Force / methods Models, Chemical Nanoparticles / chemistry Neoplasms / pathology, prevention & control* Polyglycolic Acid / chemistry |
| Grant Support | |
ID/Acronym/Agency:
|
CA-118114/CA/NCI NIH HHS; CA-125152/CA/NCI NIH HHS; R01 CA118114-03/CA/NCI NIH HHS; R01 CA125152-04/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anticarcinogenic Agents; 0/Emulsions; 0/Liposomes; 0/polylactic acid-polyglycolic acid copolymer; 26009-03-0/Polyglycolic Acid; 458-37-7/Curcumin; 50-21-5/Lactic Acid |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells.
Next Document: Inferring epidemiological parameters on the basis of allele frequencies.